Anti-adalimumab and anti-certolizumab antibodies titers after discontinuation of adalimumab: Two case reports

Mariapaola Marino, Umberto Basile, Valentina Grossi, Maria Infantino, Mariangela Manfredi, Francesca Gulli, Francesca Li Gobbi, Arianna Damiani, Fabiola Atzeni, Maurizio Benucci

Research output: Contribution to journalArticle

Abstract

Tumor necrosis factor (TNF)-α plays a key role in the pathogenesis of chronic inflammatory disorders; the discovery of TNF-blockers, neutralizing its biological activities, opened the way to a new efficacious therapeutic strategy. Unfortunately, the immunogenicity of anti-TNF drugs may trigger an adverse immune response with the occurrence of anti-drug antibodies (ADAs) impairing drug efficacy and safety. The increase of drug doses to overcome the effect of ADAs gives rise to many adverse effects inducing to the treatment discontinuation
Original languageEnglish
Pages (from-to)950-953
Number of pages4
JournalClinical Chemistry and Laboratory Medicine
Volume2019
DOIs
Publication statusPublished - 2019

Keywords

  • TNF
  • adalimumab
  • anti-TNF drugs
  • certolizumab
  • immunogenicity

Fingerprint

Dive into the research topics of 'Anti-adalimumab and anti-certolizumab antibodies titers after discontinuation of adalimumab: Two case reports'. Together they form a unique fingerprint.

Cite this